What is Abcuro?
Abcuro is at the forefront of developing first-in-class immunotherapies designed to treat autoimmune diseases and cancer. The company's innovative approach centers on the precise modulation of highly cytotoxic T cells. Its lead program, ulviprubart (ABC008), is currently undergoing clinical trials for indications such as inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. The substantial enterprise-level funding indicates a strong market belief in Abcuro's therapeutic potential and its ability to address significant unmet medical needs.
How much funding has Abcuro raised?
Abcuro has raised a total of $405M across 3 funding rounds:
Series A
$50M
Series B
$155M
Series C
$200M
Series A (2021): $50M with participation from RA Capital Management, Pontifax, Mass General Brigham Ventures, Sanofi Ventures, Hongsen Investment Group, and Samsara BioCapital
Series B (2023): $155M led by Sanofi Ventures, Redmile Group, Samsara BioCapital, and RA Capital Management
Series C (2025): $200M supported by Bain Capital, Foresite Capital, BlackRock, Sanofi Ventures, New Enterprise Associates, Eurofarma, Pontifax, Soleus Capital, Redmile Group, Mass General Brigham Ventures, Samsara BioCapital, and RA Capital Management
Key Investors in Abcuro
Bain Capital
Bain Capital is a leading global private investment firm with a broad platform that invests across private equity, growth & venture, capital solutions, credit & capital markets, and real assets. Their Special Situations team offers flexible funding tailored to specific company needs.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. They target breakthrough opportunities at the intersection of technology and biotechnology.
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products and services. They manage investments across various asset classes for institutional and individual investors.
What's next for Abcuro?
With the recent influx of major strategic investment, Abcuro is poised to accelerate its clinical development pipeline. This capital infusion is expected to support the advancement of ulviprubart through further clinical trials, potentially paving the way for regulatory submissions and eventual commercialization. The company's focus on modulating cytotoxic T cells positions it within a rapidly evolving and highly competitive field of immuno-oncology and autoimmune disease treatment. Future growth will likely involve expanding its therapeutic pipeline and potentially forging strategic partnerships to enhance market reach and development capabilities.
See full Abcuro company page
